Nearly 43.1% of U.S. adults aged 50 and over have low bone mass, a condition that significantly increases the risk of developing osteoporosis and related fractures. This growing public health concern affects millions of individuals, especially postmenopausal women, highlighting the urgent need for effective interventions to improve bone health and reduce fracture risk.
In response to this challenge, Amgen Inc., a global leader in biotechnology, has been at the forefront of developing innovative treatments for serious health conditions, including osteoporosis. With a presence in around 100 countries, Amgen has made significant strides in addressing bone-related diseases through extensive research and development efforts.
In this article, we’ll take a closer look at Amgen’s role as the manufacturer of Evenity, exploring the company’s mission, global reach, and key contributions to the ongoing fight against osteoporosis.
Key Takeaways
- Amgen is a global biotechnology leader, known for its commitment to developing innovative treatments for serious health conditions, including osteoporosis.
- The company’s work in bone health includes Evenity, a treatment designed to improve bone density and reduce the risk of fractures in postmenopausal women.
- Evenity (romosozumab) is a dual-action sclerostin inhibitor that promotes both bone formation and reduces bone resorption, making it a unique approach to managing osteoporosis.
- Amgen partners with UCB to develop and commercialize Evenity. This strategic collaboration leverages Amgen’s expertise in clinical research and product development alongside UCB’s experience in regulatory strategy and market access.
- Patient selection for Evenity is based on specific criteria, including low bone mineral density, a history of fragility fractures, and prior treatment failure or intolerance. Pre-treatment evaluations, including serum calcium levels and cardiovascular risk assessments, are essential.
- Amgen offers reimbursement and patient access programs, as well as clinical education resources for healthcare providers, to ensure optimal patient care and adherence to treatment plans.
- Amgen’s broader portfolio includes therapies like Prolia (denosumab), further strengthening its position in bone health management and providing healthcare providers with a range of options tailored to the needs of patients with osteoporosis.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. If you’re looking to buy Evenity for your practice, our sales representatives will give you guidance. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Company Overview and Mission of Amgen Inc.
Amgen is a global biotechnology powerhouse that transforms scientific breakthroughs into innovative therapies designed to restore health and well-being. As the manufacturer of Evenity, Amgen harnesses cutting-edge research and rigorous clinical development to serve patients, particularly those battling osteoporosis.
The company’s commitment to ethical practices, superior quality, and relentless focus on patient-centered care underscores its mission to make a meaningful difference in healthcare. Amgen’s mission and values are built on these core pillars:
- Patient-Centric Innovation: Delivering breakthrough therapies that significantly improve health outcomes.
- Scientific Excellence: Leveraging advanced research and the scientific method to drive the development of new products.
- Ethical Integrity: Upholding the highest standards of ethics and quality in every aspect of its work.
By prioritizing transparency and collaboration, Amgen continually turns scientific discoveries into effective treatments. This dedication not only underscores its leadership in the biotechnology field but also lays the foundation for its robust portfolio, which includes Evenity for the management of osteoporosis.
Role of Amgen and UCB in Product Development
A strategic partnership between Amgen and UCB led to the development of Evenity, an innovative treatment for osteoporosis that reduces bone fracture risk. These companies combine their expertise in clinical research, regulatory affairs, and commercialization to refine Evenity’s therapeutic benefits for patients worldwide.
- Amgen leads in clinical treatment research, product development, and manufacturing excellence.
- UCB drives regulatory strategy, manages regional market access, and oversees commercialization.
This strong partnership between Amgen and UCB highlights their joint commitment to transforming scientific innovation into a real-world solution for osteoporosis, ensuring patients receive a safe and effective treatment globally.
In particular, Evenity has received approval from the US Food and Drug Administration (FDA). Before practitioners use the product, it’s essential to study and understand Evenity’s prescribing information, which provides critical details on drug dosage, administration, and patient suitability.
The Evenity Manufacturer’s Broader Bone Health Portfolio
Amgen’s portfolio goes well beyond Evenity (romosozumab), offering a range of treatments designed to reduce fracture risk and improve skeletal strength. This comprehensive approach reflects Amgen’s commitment to advancing clinical products or therapeutics for osteoporosis and related disorders.
Amgen’s broader portfolio includes multiple products that target specific aspects of skeletal care. These therapies enable clinicians to tailor treatment strategies that meet the diverse needs of patients managing osteoporosis, ensuring comprehensive and effective patient care.
- Evenity (romosozumab): A dual-action sclerostin inhibitor that both promotes bone formation and modestly inhibits bone resorption. This therapy provides rapid gains in bone density within a 12-month period.
- Prolia (denosumab): A monoclonal antibody that targets the RANK ligand, effectively decreasing bone resorption and reducing fracture risk.
Amgen’s integrated strategy in bone health management underscores its commitment to offering a variety of innovative treatments that address both anabolic and antiresorptive therapy pathways. This dual approach enhances treatment outcomes and improves patient quality of life.
Information on Amgen Support for Providers and Ongoing Research
Amgen offers critical information and support programs to healthcare providers while actively advancing research in osteoporosis management. This collaborative framework provides medical professionals with access to essential resources and the latest scientific insights. In turn, this leads to enhanced patient care and ensured safety throughout every stage of treatment.
To support providers, Amgen offers:
- Reimbursement and Patient Access Programs: Helping patients navigate coverage issues. For example, insurance and Medicare navigation to help patients understand how to pay for therapy.
- Comprehensive Clinical Education: Providing online resources and training to keep providers informed. This includes provider access to prescribing information for clear dosing guidance.
- Detailed Prescribing Information: Delivering clear guidance on treatment protocols and best practices. Notably, educational resources on fracture prevention and long-term care in osteoporosis.
Additionally, Amgen is committed to continually improving bone health through romosozumab and other drugs. The company drives innovation through ongoing clinical trials, post-marketing surveillance, and real-world evidence studies. These research initiatives inform future practice guidelines and therapeutic advancements, ensuring Evenity remains at the forefront of osteoporosis treatment and patient safety.
Conclusion
Amgen Inc. stands out as a key player in the biotechnology field with its commitment to advancing treatments for osteoporosis. Evenity’s development, in partnership with UCB, exemplifies their dedication to addressing low bone mass and promoting better bone health. Their innovative therapies help improve patient outcomes and highlight the importance of combining ethical practices with scientific excellence.
With a diverse portfolio that includes treatments like Prolia, Amgen continues to support healthcare providers and enhance patient care. This includes access to insurance, prescribing information, and medical materials. By prioritizing education and access, Amgen ensures patients receive the necessary tools to manage osteoporosis effectively, fostering healthier lives.
FAQs
1. What is Evenity treatment, and who manufactures it?
Evenity is an innovative treatment for osteoporosis, manufactured by Amgen Inc. in collaboration with UCB.
2. How does Amgen contribute to osteoporosis management?
Aside from being the Evenity manufacturer, Amgen focuses on developing breakthrough therapies. The company offers a comprehensive portfolio that addresses various aspects of bone health. This helps to reduce fracture risk and improve skeletal strength.
3. What support does Amgen provide to healthcare providers?
The Evenity manufacturer offers resources, including reimbursement (insurance or Medicare insurance) and patient access programs, as well as clinical education. These help providers enhance patient care and effectively manage osteoporosis treatment.
References
- Centers for Disease Control and Prevention. Osteoporosis or Low Bone Mass in Older Adults: United States, 2017–2018. www.cdc.gov. Published March 26, 2021. https://www.cdc.gov/nchs/products/databriefs/db405.htm
- Mission and Values | Amgen. Amgen Inc. Accessed June 13, 2025. https://www.amgen.com/about/mission-and-values?_gl=1
